Partners

COORDINATOR

Luxembourg National Research Fund (FNR)

FNR_logo_english LARGE transparentwww.fnr.lu

The Luxembourg National Research Fund (FNR) is the main funder of research activities in Luxembourg.  The FNR invests public funds and private donations into research projects in various branches of science and the humanities, with an emphasis on selected core strategic areas. Furthermore, FNR supports and coordinates activities to strengthen the link between science and society and to raise awareness for research. FNR also advises the Luxembourg government on research policy and strategy.

Role and contribution to the project:

In the Clinnova TEAMING Phase 1 project, FNR will be leader of the following work packages:

  • Governance and management planning
  • Business plan production
  • Project management

FNR will also be responsible for the following tasks:

  • Definition of the legal status of the Centre of Excellence
  • Definition of the governance rules for the Centre of Excellence
  • Financial planning
  • Teaming project communication
  • Business plan writing – First draft
  • Business plan writing – Final version
  • Project coordination
  • Administration management

MAIN PARTNERS

Luxembourg Institute of Health (LIH)

CRP_154501_LIH_logo_bat  www.lih.lu

The Luxembourg Institute of Health (LIH) is a public research organisation at the forefront of biomedical sciences. With its strong expertise in oncology, infection and immunity as well as population health, its research activities impact on people’s health.

At the LIH, devoted scientists investigate disease mechanisms to develop new diagnostics, innovative therapies and effective tools to implement personalised medicine. The institution is the first supplier of public health information in Luxembourg and also includes the Integrated Biobank of Luxembourg (IBBL), which collects, stores and analyses high quality biological samples to support biomedical research.

Role and contribution to the project:

In the Clinnova TEAMING Phase 1 project, LIH will be leader of the following work packages:

  • Resources planning
  • International positioning and communication

LIH will also be responsible for the following tasks:

  • Definition of the intellectual property rights management rules for the Centre of Excellence
  • Infrastructure and equipment planning
  • Administrative resources and processes planning
  • Research and innovation benchmark
  • Market, context and competition research
  • Marketing strategy development
  • Dissemination and exploitation plan
  • Risk management

Luxembourg Centre for Systems Biomedicine (LCSB) / University of Luxembourg

uni lu & lcsb logo www.uni.lu/lcsb

The University of Luxembourg, founded in 2003, is one of the youngest universities in Europe. It is a research-oriented, international and multilingual university with over 6,000 students from more than 100 different countries.

Systems biomedicine has been identified as a high priority research area. For this purpose, the government of Luxembourg has launched a major programme in personalized medicine, which included the establishment of the Luxembourg Centre for Systems Biomedicine (UL-LCSB) in 2009, with Prof. Rudi Balling appointed as founding director.

The mission of the Luxembourg Centre for Systems Biomedicine (UL-LCSB) is the analysis of disease mechanisms using a wide range of bioinformatics, computational and systems biology methods. High throughput genomics-, proteomics- and metabolomics-technology are used as a basis for the mathematical descriptions of disease networks and the modeling and simulation of disease pathogenesis. A major focus of the centre is on the analysis of neurodegenerative diseases, particularly Parkinson’s disease. Scientists at the Luxembourg Centre for Systems Biomedicine have intensive knowhow in studying complex biological systems, particularly in disease network inference and analysis.

Role and contribution to the project 

In the Clinnova TEAMING Phase 1 project, UL-LCSB will be leader of the following work packages:

  • Research and innovation strategy planning
  • Risk management planning

UL-LCSB will also be responsible for the following tasks:

  • Definition of the organisational model of the Centre of Excellence
  • Human resources planning and human resources policy development
  • Long-term research and innovation strategy
  • Business model definition
  • Network development
  • Ethical issues management
  • Quality management

Center for Innovativ Medicinsk Teknologi, Region Syddanmark (CIMT-RSD)

CIMTouh_southern dk joint logoUni Southern DK

www.cimt.dkregionsyddanmark.dkouh.dk / sdu.dk

The Center for Innovativ Medicinsk Teknologi (CIMT) based in south Denmark has three consortium partners: Region of Southern Denmark (RSD), Odense University Hospital (OUH) and Southern Denmark University (SDU). For the Clinnova proposal, the consortium is represented by the legal entity RSD.

RSD is one of five regions in Denmark, and covers approximately 1.2 million inhabitants. The main task of the region is to run the health services in Southern Denmark. The region operates four main hospital units – OUH being the largest – and the hospitals collaborate with up to 800 GPs to provide medical treatment. Increasingly over the past 10 years, the region has focused on eHealth and telemedicine – both in research projects but also in implementation. All hospitals in the region have implemented telemedicine services, and the level of electronic communication is very high as almost 6 million messages are transmitted electronically every month between hospitals, GPs, municipalities, pharmacies, therapists and other health institutions in the Region.

SDU is the third largest university in Denmark and is a leading centre of research with five faculties. The Department of Clinical Research is one of eight institutes at the Faculty of Health Sciences at the university and comprises 41 Research Units, 5 centres of excellence, as well as a centre of evidence based medicine, and CIMT. The department houses 95 Professors and approximately 500 other academic staff and aims at educating and performing research at a high international level. The total research output comprises approximately >1350 peer-reviewed publications per year.

CIMT undertakes the following medical operational and research tasks across OUH and SDU:

  • Development, testing and evaluation of innovative technologies at OUH
  • Establishment and implementation of research projects within innovative clinical technology
  • Development and execution of international projects that support the overall innovation strategy
  • Ensuring the documentation needed for decision support related to investments to executive staff
  • Coordination of activities on a regional level (together with the Health Innovation Centre of Southern Denmark, Welfare Tech, the Municipality of Odense and the department of Regional Development, etc.)
  • Representation of OUH, SDU and sometimes RSD in relevant national and international networks, associations, projects and activities

Role and contribution to the project

In the Clinnova TEAMING Phase 1 project, CIMT-RSD will provide lead input, i.e. advice/coaching to the Luxembourgish partners and lead contribution, for the following tasks:

  • Administrative resources and process planning
  • Research and innovation benchmark
  • Market, context and competition research
  • Marketing strategy development
  • Ethical issues management
  • Quality management

Nationale Centrum für Tumorerkrankungen, Deutsches Krebsforschungszentrum (NCT-DKFZ)

DKFZ_NCT_22www.nct-heidelberg.de / www.dkfz.de

The Nationale Centrum für Tumorerkrankungen (NCT) is dedicated to clinical translation of cancer research. It was established in 2005 on the basis of the Deutsches Krebsforschungszentrum (DKFZ) together with Universitätsklinikum Heidelberg (UKL-HD) and Deutsche Krebshilfe.

DKFZ is the largest biomedical research centre in Germany. Established in 1964, DKFZ pursues the mission to unravel cancer causes and mechanisms.

UKL-HD is among the largest and most prestigious medical centres in Europe, with approximately 800,000 patient visits annually. In more than 40 clinics, 59,700 inpatients are seen every year, and 40% of these contacts are cancer-related. Modern premises, state-of-the-art equipment and efficient workflows enable high-performance medicine.

As an exceptional alliance, NCT-DKFZ has rapidly grown into the prime comprehensive cancer centre in Germany. In 2015, approx. 10.000 newly diagnosed cancer patients were seen at NCT-DKFZ and more than 17.000 anti-tumour therapies were administered.

NCT-DKFZ pursues personalized oncology as a centre-wide master strategy. This strategy coordinates all activities towards individualized cancer medicine, including patient-oriented diagnostic and clinical radio-oncology, immunology and prevention.

Role and contribution to the project

In the Clinnova TEAMING Phase 1 project, NCT-DKFZ will provide lead input, i.e. advice/coaching to the Luxembourgish partners and lead contribution, for the following tasks:

  • Infrastructure and equipment planning
  • Human resources planning and human resources policy development
  • Long-term research and innovation strategy
  • Business model definition
  • Network development
  • Dissemination and exploitation plan
  • Risk management